BCG Vaccination Program Mitigates COVID19 Related Mortality: A Reality Check

Area of Science:

• Immunology
• Infectious Diseases
• Public Health

Background:

• Coronavirus Disease 19 (COVID-19) has caused a global pandemic with significant mortality rate variations.
• Underlying immunity factors, including vaccination status, may influence COVID-19 outcomes.
• The Bacillus Calmette-Guerin (BCG) vaccine is known to provide broad protection against various infections.

Purpose of the Study:

• To investigate the potential role of BCG vaccination in modulating COVID-19 mortality.
• To analyze the relationship between national BCG vaccination policies and COVID-19 impact.
• To explore the concepts of trained immunity and cross-protection conferred by BCG vaccination in the context of SARS-CoV-2.

Main Methods:

• Review and contrast of global BCG vaccination program data with COVID-19 mortality rates.
• Analysis of existing literature on BCG's effects on trained immunity and cross-protection.
• Comparative analysis of COVID-19 impact in countries with and without universal BCG policies.

Main Results:

• Countries with universal BCG vaccination policies appear to be less severely affected by COVID-19 compared to those without.
• BCG vaccination demonstrates a potential for broad protection against respiratory and other infections.
• Observed variations in COVID-19 mortality may be partly explained by differing national BCG childhood vaccination policies.

Conclusions:

• BCG vaccination may offer a protective effect against COVID-19, potentially reducing morbidity and mortality.
• The findings suggest that BCG could be a valuable tool in managing the COVID-19 pandemic.
• National policies on childhood BCG vaccination could be a significant factor in explaining global disparities in COVID-19 impact.